Archive for the ‘levitra’ tag
ED agent improves sexual pleasure in both partners
Treatment with PDE-5 inhibitor shows improvements in several satisfaction domains
The phosphodiesterase type-5 inhibitor vardenafil (Levitra) significantly improves sexual pleasure and treatment satisfaction in both men with erectile dysfunction and their partners. according to study results presented at the European Association of Urology annual congress here.
More than one-half of all men older than age 40 years are estimated to have some degree of ED. Yet, only 10% of the approximately 30 million men affected in the United States seek treatment for the condition. For the majority of those who do, PDE-5 inhibitors—sildenafil citrate (Viagra), tadalafil (Cialis), and vardenafil—are recognized as first-line therapy for ED management.
“In this report, the rote and impact of the partner is highlighted and clearly shows that effective treatment of male erectile dysfunction yields measurable improvements in partner sexual satisfaction,” said study co-author Gerald Brock, MD, associate professor of urology at St. Joseph’s Medical Center, Lawson Research Institute, London, Ontario, Canada. “While often ignored, ultimately successful erectile dysfunction treatment satisfaction of the male requires that the partner obtains an enhanced experience as well.”
Oral ED agent has rapid onset of action, study shows
The onset of action may be very rapid—within 10 minutes—in some men who take vardenafil (Levitra) to treat erectile dysfunction, according to the results of a multinational study.
Designed to identify the earliest time to onset of action leading to successful sexual intercourse after vardenafil dosing, the “Onset of vardenafil in men with erectile dysfunction” (ONTIME) trial—overseen by Luc Valiquette. MD, professor of urology at the Hospital Saint-Luc du CHUM in Montreal—randomized 732 patients to treatment with vardenafil, 10 mg; vardenafil, 20 mg; or placebo. The study participants had a baseline International Index of Erectile Function score of 13.4 (moderate severity), and all had demonstrated u response to vardenafil.
,p> Each participant was instructed to initiate sexual activity immediately after taking the medication and was issued a stopwatch to time the interval between dosing and attainment of erection perceived to be adequate for penetration with subsequent intercourse completion—recorded as a positive response to question 3 in the Sexual Encounter Profile (SEP3). Read the rest of this entry »